JAMA Psychiatry
January 29, 2020
Z. Segal, Sona Dimidjian, A. Beck et al.
Importance Patients with residual depressive symptoms face a gap in care because few resources, to date, are available to manage the lingering effects of their illness. Objective To evaluate the effectiveness for treating residual depressive symptoms with Mindful Mood Balance (MMB), a web-based application that delivers mindfulness-based cognitive therapy, plus usual depression care compared...
Mindfulness
April 29, 2019
J. Michalak, Catherine Crane, C. Germer et al.
ObjectivesMindfulness-based interventions (MBIs) like mindfulness-based stress reduction (MBSR) and mindfulness-based cognitive therapy (MBCT) teach mindfulness in a group-based format. Empirical research has shown that many therapists working in individual therapy integrate mindfulness practices (e.g., body scan, sitting meditation) into their treatments. However, research on this topic is in...
Journal of Consulting and Clinical Psychology
February 1, 2019
Z. Segal, A. Anderson, T. Gulamani et al.
Background: To investigate whether usage of treatment-acquired regulatory skills is associated with prevention of depressive relapse/recurrence. Method: Remitted depressed outpatients entered a 24-month clinical follow up after either 8 weekly group sessions of cognitive therapy (CT; N = 84) or mindfulness-based cognitive therapy (MBCT; N = 82). The primary outcome was symptom return meeting...
Current Opinion in Psychology
January 28, 2019
Z. Segal, Sona Dimidjian, Rachel Vanderkruik et al.
Mindfulness Based Cognitive Therapy is a multimodal intervention that integrates training in mindfulness meditation and the cognitive theory of affective disorder. This hybrid nature may provide an advantage in the prevention field that addresses the critical need for enhancing wellness among people with recurrent mood disorders. Despite the robust evidence base for MBCT, its penetration at the...
BMC Complementary and Alternative Medicine
March 11, 2014
Stuart J. Eisendrath, Erin P Gillung, Kevin L. Delucchi et al.
BackgroundMajor depressive disorder (MDD) is the leading cause of disability in the developed world, yet broadly effective treatments remain elusive. Up to 40% of patients with depression are unresponsive to at least two trials of antidepressant medication and thus have “treatment-resistant depression” (TRD). There is an urgent need for cost-effective, non-pharmacologic, evidence-based...